E-LIB Suche - Ergebnisse für: Subbiah, V

1

63P Activity and safety of FGFR inhibitors in pan-cancer pa..:

Grochot, R.M. ; Joshi, K. ; Sathanantham, G....
ESMO Open. 9 (2024) - p. 102292 , 2024

Link: https://doi.org/10.1016/..

2

Open-label, dose-escalation FIGHT-101 study of pemigatinib ..:

Saleh, M. ; Barve, M. ; Subbiah, V....
ESMO Open. 9 (2024) 7 - p. 103625 , 2024

Link: https://doi.org/10.1016/..

3

PP01.50 EMERGE-201: Phase 2 Basket Study of Lurbinectedin M..:

Spigel, D. ; Galsky, M.D. ; Heeke, A.L....
Journal of Thoracic Oncology. 18 (2023) 3 - p. e31 , 2023

Link: https://doi.org/10.1016/..

4

Cancer: slaying the nine-headed Hydra:

Adashek, J.J. ; Subbiah, V. ; Westphalen, C.B....
Annals of Oncology. 34 (2023) 1 - p. 61-69 , 2023

Link: https://doi.org/10.1016/..

5

Everolimus in combination with vandetanib in children, adol..:

Phadnis, S. ; Wang, X. ; Daw, N.C....
ESMO Open. 8 (2023) 6 - p. 101609 , 2023

Link: https://doi.org/10.1016/..

6

EP13.07-06 Efficacy of Platinum Given after Lurbinectedin i..:

Trigo, J.M. ; Besse, B. ; Zaman, K....
Journal of Thoracic Oncology. 18 (2023) 11 - p. S708-S709 , 2023

Link: https://doi.org/10.1016/..

7

Cracking KRASG12C across all solid tumors: the new kid on t..:

Bhamidipati, D. ; Subbiah, V.
ESMO Open. 8 (2023) 4 - p. 101591 , 2023

Link: https://doi.org/10.1016/..

8

Precision oncology for BRAF-mutant cancers with BRAF and ME..:

Gouda, M.A. ; Subbiah, V.
ESMO Open. 8 (2023) 2 - p. 100788 , 2023

Link: https://doi.org/10.1016/..

9

Sodium fluoride (Na18F) PET Response Criteria in Solid Tumo..:

Kairemo, K. ; Gouda, M.A. ; Buschhorn, L....
ESMO Open. 8 (2023) 4 - p. 101575 , 2023

Link: https://doi.org/10.1016/..

10

82TiP A modular, open-label, phase I/II study to evaluate t..:

Gianoukakis, A.G. ; Arnold, S.M. ; Kahn, S.A....
Journal of Thoracic Oncology. 18 (2023) 4 - p. S87-S88 , 2023

Link: https://doi.org/10.1016/..

11

Safety and efficacy of pralsetinib in RET fusion–positive n..:

Griesinger, F. ; Curigliano, G. ; Thomas, M....
Annals of Oncology. 33 (2022) 11 - p. 1168-1178 , 2022

Link: https://doi.org/10.1016/..

12

Lurbinectedin, a selective inhibitor of oncogenic transcrip..:

Boni, V. ; Pistilli, B. ; Braña, I....
ESMO Open. 7 (2022) 5 - p. 100571 , 2022

Link: https://doi.org/10.1016/..

13

FIGHT-101, a first-in-human study of potent and selective F..:

Subbiah, V. ; Iannotti, N.O. ; Gutierrez, M....
Annals of Oncology. 33 (2022) 5 - p. 522-533 , 2022

Link: https://doi.org/10.1016/..

14

DNA Damage Response (DDR) Basket of Baskets (D-BOB) Trial: ..:

Ngoi, N. ; Pilie, P.G. ; Piha-Paul, S.A....
European Journal of Cancer. 174 (2022) - p. S10 , 2022

Link: https://doi.org/10.1016/..

15

Identifying FGFR2 fusions/rearrangements in cholangiocarcin..:

Schram, A. ; Borad, M. ; Sahai, V....
European Journal of Cancer. 174 (2022) - p. S116 , 2022

Link: https://doi.org/10.1016/..